A psychedelic therapy screening assessment is the structured clinical process that determines whether you are a suitable candidate for psilocybin or similar modalities. For high-performing individuals, it covers psychiatric history, cardiovascular health, current...
The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD in August 2024, and as of mid-2026 that decision stands. MDMA remains a Schedule I substance in the United States, meaning the only legal access pathways are through active...
This psychedelic therapy FAQ compiles the most common and most important questions from people seriously considering psilocybin or other psychedelic-assisted approaches. The answers here are grounded in current clinical research, verified legal data, and practical...
The JOM11 psychedelic executive program is JourneyOM’s structured, concierge-level pathway for senior leaders who want to address burnout, cognitive rigidity, or performance plateaus through professionally supported psychedelic therapy. Built around eleven...
Psilocybin grief therapy is an emerging, clinically-studied approach for individuals whose grief has persisted well beyond the expected acute phase. For high-functioning professionals who have maintained performance while carrying unprocessed loss, the evidence points...
Research into psilocybin sleep insomnia effects is still early, but the findings are genuinely interesting. Studies show psilocybin alters REM sleep and slow-wave activity in ways that parallel some antidepressants, and preliminary data suggests sleep quality may...
